Welcome to our dedicated page for IPN news (Ticker: IPN), a resource for investors and traders seeking the latest updates and insights on IPN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IPN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IPN's position in the market.
Ipsen (Euronext: IPN; ADR: IPSEY) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Cabometyx® in combination with Opdivo® for treating advanced renal cell carcinoma (aRCC). The European Commission will review this recommendation, with a final decision expected soon. This follows successful results from the Phase III CheckMate -9ER trial, showing significant improvements in progression-free survival and overall survival compared to sunitinib.
Ipsen announced nine abstracts focused on neuroendocrine tumors (NETs) during the ENETS Conference, including data from the CLARINET FORTE study. This study showed no deterioration in patients' quality of life (QoL) when treated with lanreotide autogel. Pharmacokinetic data confirmed proportional increases with higher dosing without additional safety concerns. Additionally, an economic model indicated potential healthcare savings in the UK by increasing independent home administration of lanreotide, reducing nurse visits and costs by 16.4%.
Ipsen reported its 2020 financial results, achieving €2.592 million in sales, a 3.0% increase at constant currency. Specialty Care sales grew by 5.9%, while Consumer Healthcare declined by 21.3% due to COVID-19. Core Operating margin improved to 32.0%, with a net profit of €610.5 million, reflecting an 8.4% increase. Free Cash Flow rose significantly to €646.4 million, aided by operational efficiencies. The company set a 2021 sales growth guidance of over 4.0% and proposed a dividend of €1.00 per share. Ipsen emphasizes its ongoing focus on oncology and external innovations.
Ipsen (Euronext: IPN; ADR: IPSEY) announced it will present new data at the ASCO GU Symposium from February 11-13, 2021. The focus will be on ten abstracts related to genitourinary cancers, highlighting treatment advancements. Key findings include extended data from the CheckMate -9ER trial demonstrating that cabozantinib combined with nivolumab may improve survival for advanced renal cell carcinoma (RCC) patients. Significant real-world evidence also suggests cabozantinib offers higher response rates compared to other TKIs in metastatic RCC cases.
Ipsen has appointed Gwenan White as Executive Vice President, Communications and Public Affairs, effective March 2021. She will oversee global communications and report to CEO David Loew, contributing to the company's strategy, Focus. Together. For patients & society. White has extensive experience in communications from her previous role at Novartis and will strengthen Ipsen’s global stakeholder relationships. This leadership change aims to enhance the visibility of Ipsen's innovative medicines and align communications with strategic goals.
Ipsen announced analyses of Phase III clinical trial data for Dysport® (abobotulinumtoxinA), presented at the TOXINS 2021 conference. The studies focus on treatment intervals across five patient populations, showing significant long durations of response. Results indicated that a substantial percentage of patients did not require retreatment within 12-16 weeks: CD (72.6-81.5%), ALL (20.1-32.0%), AUL (24.0-36.9%), PLL (72.8-93.8%), and PUL (19.6-67.0%). Safety outcomes were consistent with expectations. Ipsen aims to enhance understanding of spasticity and dystonia treatment outcomes.
